March 2013
MondayMorning;3/25/2013, Vol. 21 Issue 11, p1
The article offers news briefs related to the U.S. Food & Drug Administration (FDA) and healthcare industry as of March 25, 2013. Titan Pharmaceuticals Inc. has won the support of a experts panel of that approved its opioid dependence treatment. FDA has warned about eye infection which is linked to an unapproved Avastin syringes created by a pharmacy of Georgia. Drug advisory board of European Medicines Agency has approved a blood-thinner Xarelto developed by Bayer AG.


Related Articles

  • FDA urges withdrawal of poultry drug from market.  // Food Engineering;Dec2001, Vol. 73 Issue 12, p24 

    Focuses on the request made by the Food and Drug Administration for Bayer A.G. to remove the poultry drug Baytril from the ground. Grounds for the petition; Side effects in using the drug; Impact of the decision on the business operations of Bayer.

  • Injections raise safety question. Charters, Lynda // Ophthalmology Times;3/1/2012, Vol. 37 Issue 5, p20 

    The article focuses on the presentation of doctor Roger A. Goldberg at American Academy of Ophthalmology's annual meeting on Streptococcus endophthalmitis outbreaks and steps taken by the Bascom Palmer Eye Institute to prevent contamination risk on syringe preparation. Goldberg states that 12...

  • GENERICS NEWSLINE.  // Monthly Prescribing Reference;Jan2012, Vol. 28 Issue 1, pA-8 

    The article presents news briefs related to generic drugs in the U.S. It mentions that the U.S. Food and Drug Administration (FDA) has given approval to Mylan for its Abbreviated New Drug Application (ANDA) for Eprosartan Mesylate Tablet. It states that Watson Laboratories has received approval...

  • First in its class. Rodgers, Katie // Drug Topics;10/9/95, Vol. 139 Issue 19, p30 

    Reports on the Food and Drug Administration's approval for the release of Bayer AG's Precose acarbose drug for the treatment of noninsulin-dependent diabetes mellitus. Caution against dual therapy with acarbose and other antidiabetic drugs; Side effects of acarbose during clinical trials.

  • Pharma: Other News To Note.  // BioWorld Today;3/16/2012, Vol. 23 Issue 42, p7 

    This section offers news briefs from the pharmaceutical industry, including the approval granted by the U.S. Food and Drug Administration (FDA) to a new indication for Natazia (estradiol valerate and estradiol valerate/dienogest) tablets from Bayer AG for the treatment of heavy menstrual bleeding.

  • News Briefs. D.T. // Dermatology Times;Feb2002, Vol. 23 Issue 2, p15 

    Reports developments related to medicine in the U.S. as of February 2002. Creation of advisory panel to monitor drug marketing by the Food and Drug Administration; Evaluation of Baycol and GlaxoSmithKline drugs from Bayer AG; Prevention on the conflict of interest in physicians during clinical...

  • Avastin Gets More Time for Review.  // Pharmaceutical Representative;Oct2010, Vol. 40 Issue 10, p10 

    The article accounts on the report issued by the U.S. Food and Drug Administration regarding the extension of the review period for Avastin, a drug used to treat cancer including cancer of the breast, lungs, colon, brain, and kidneys.

  • Medicare to cover expensive cancer treatments.  // PharmacoEconomics & Outcomes News;7/16/2011, Issue 633, p11 

    The article reports on the plan of Medicare to cover Avastin bevacizumab for breast cancer treatment regardless of the decision of the U.S. Food and Drug Administration (FDA) to rescind Avastin approval for such indication in July 2011.

  • Most Doctors Back Avastin Withdrawal.  // Chain Drug Review;2/28/2011, Vol. 33 Issue 4, p93 

    The article reports on the support of fifty-eight percent of physicians in a poll by Sermo, on the move of the Food and Drug Administration (FDA) to pull the breast cancer indication for Avastin from the market.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics